Diagnostic accuracy of the point-of-care standard G6PD test™ (SD Biosensor) for glucose-6-phosphate dehydrogenase deficiency: a systematic review and meta-analysis
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Background: Glucose-6-Phosphate Dehydrogenase deficiency (G6PDd) is a common genetic enzymopathy that can induce haemolysis triggered by various factors, including some anti-malarial drugs. Although many Point-of-Care (PoC) tests, such as Standard G6PD™ are available to detect G6PDd, its pooled diagnostic test accuracy (DTA) remains unknown. Methods: To estimate the DTA of StandG6PD-BS at various thresholds of G6PDd, a systematic review with a DTA meta-analysis were conducted, searching EMBASE, MEDLINE, and SciELO databases up to April 4, 2024.The included studies were those that measured G6PD activity using StandG6PD-BS (reference test) and spectrophotometry (gold standard) in patients suspected of having G6PDd. The risk of bias (RoB) of the studies was assessed using the QUADAS-2 tool and the certainty of evidence (CoE) with the GRADE approach. For the estimation of within-study DTA, a random-effect bivariate meta-analysis was performed to determine the pooled sensitivity and specificity for 30%, 70%, and 80% enzyme levels’ thresholds, and a graphical analysis of the heterogeneity using crosshair and Confidence Regions on receiver operating characteristic (ROC) space plots. Results: After screening 2496 reports, four studies were included with 7864 participants covering all thresholds. Two studies had high RoB in QUADAS-2 domains 2 and 3, and the others had low RoB, with low, moderate, and high heterogeneity at the 30%, 70%, and 80% thresholds, respectively. The pooled sensitivity was 99.1%, 95.7%, and 90% for 30%, 70%, and 80% thresholds, respectively. The pooled specificity was 97.4%; 92.9%; and 89.0% for 30%, 70%, and 80% thresholds, respectively. Conclusion: StandG6PD-BS is a PoC test with high sensitivity and specificity to detect G6PDd at different thresholds.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Of the diagnostic approaches, spectrophotometry is the gold standard method to identify the activity of G6PDd [39].”
From Pooled prevalence of Glucose-6-phosphate dehydrogenase deficiency among malaria patients in Ethiopia: a systematic review and meta-analysis (2026) · cites this paper as [39]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rayyan-a web and mobile app for systematic reviews.
Ouzzani, M., Hammady, H., Fedorowicz, Z., & Elmagarmid, A. (2016) · Systematic Reviews · doi:10.1186/s13643-016-0384-4 · Cited by 26,092
QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies
Whiting, P. F., Rutjes, A. W. S., Westwood, M. E., Mallett, S., Deeks, J. J., Reitsma, J. B., Leeflang, M. M. G., Sterne, J. A. C., Bossuyt, P. M. M., & the QUADAS-2 Group* (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-155-8-201110180-00009 · Cited by 14,199
Reitsma, J. B., Glas, A. S., Rutjes, A. W. S., Scholten, R. J. P. M., Bossuyt, P. M., & Zwinderman, A. H. (2005) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2005.02.022 · Cited by 3,369
Cochrane Handbook for Systematic Reviews of Diagnostic Test Accuracy
(2023) · doi:10.1002/9781119756194 · Cited by 757
Research works printed but not linked: 32
- Howes RE, Battle KE, Satyagraha AW, Baird JK, Hay SI. G6PD deficiency: global distribution, genetic variants and primaquine therapy. The epidemiology of Plasmodium vivax. Adv Parasitol. 2013;81:133–201. · DOI · Paper page
- Bancone G, Chu CS. G6PD variants and haemolytic sensitivity to primaquine and other drugs. Front Pharmacol. 2021;12: 638885. · DOI
- Nkhoma ET, Poole C, Vannappagari V, Hall SA, Beutler E. The global prevalence of glucose-6-phosphate dehydrogenase deficiency: a systematic review and meta-analysis. Blood Cells Mol Dis. 2009;42:267–78. · DOI · Paper page
- Howes RE, Dewi M, Piel FB, Monteiro WM, Battle KE, Messina JP, et al. Spatial distribution of G6PD deficiency variants across malaria-endemic regions. Malar J. 2013;12:418. · DOI · Paper page
- Chu CS, White NJ. The prevention and treatment of Plasmodium vivax malaria. PLoS Med. 2021;18: e1003561. · DOI · Paper page
- WHO. World Malaria Report 2023. Geneva: World Health Organization; 2023.
- WHO. Testing for G6PD deficiency for safe use of primaquine in radical cure of P. vivax and P. ovale malaria: policy brief. Geneva: World Health Organization; 2016.
- WHO. Malaria Policy Advisory Committee Meeting. Point-of-care G6PD testing to support safe use of primaquine for the treatment of vivax malaria. Geneva: World Health Organization; 2015.
- LaRue N, Kahn M, Murray M, Leader BT, Bansil P, McGray S, et al. Comparison of quantitative and qualitative tests for glucose-6-phosphate dehydrogenase deficiency. Am J Trop Med Hyg. 2014;91:854–61. · DOI · Paper page
- Espino FE, Bibit JA, Sornillo JB, Tan A, von Seidlein L, Ley B. Comparison of three screening test kits for G6PD enzyme deficiency: implications for its use in the radical cure of vivax malaria in remote and resource-poor areas in the Philippines. PLoS ONE. 2016;11: e0148172. · DOI · Paper page
- Osorio L, Carter N, Arthur P, Bancone G, Gopalan S, Gupta SK, et al. Performance of BinaxNOW G6PD deficiency point-of-care diagnostic in P. vivax-infected subjects. Am J Trop Med Hyg. 2015;92:22–7. · doi:10.4269/ajtmh.14-0298
- Ley B, Bancone G, von Seidlein L, Thriemer K, Richards JS, Domingo GJ, et al. Methods for the field evaluation of quantitative G6PD diagnostics: a review. Malar J. 2017;16:361. · DOI · Paper page
- Brito MAM, Peixoto HM, de Almeida ACG, de Oliveira MRF, Romero GAS, Moura-Neto JP, et al. Validation of the rapid test Carestart(tm) G6PD among malaria vivax-infected subjects in the Brazilian Amazon. Rev Soc Bras Med Trop. 2016;49:446–55. · doi:10.1590/0037-8682-0134-2016
- Adissu W, Brito M, Garbin E, Macedo M, Monteiro W, Mukherjee SK, et al. Clinical performance validation of the STANDARD G6PD test: a multi-country pooled analysis. PLoS Negl Trop Dis. 2023;17: e0011652. · doi:10.1371/journal.pntd.0011652
- Schünemann HJ, Mustafa RA, Brozek J, Steingart KR, Leeflang M, Murad MH, et al. GRADE guidelines: 21 part 1. Study design, risk of bias, and indirectness in rating the certainty across a body of evidence for test accuracy. J Clin Epidemiol. 2020;122:129–41. · DOI · Paper page
- Schünemann HJ, Mustafa RA, Brozek J, Steingart KR, Leeflang M, Murad MH, et al. GRADE guidelines: 21 part 2. Test accuracy: inconsistency, imprecision, publication bias, and other domains for rating the certainty of evidence and presenting it in evidence profiles and summary of findings tables. J Clin Epidemiol. 2020;122:142–52. · DOI · Paper page
- Pal S, Myburgh J, Bansil P, Hann A, Robertson L, Gerth-Guyette E, et al. Reference and point-of-care testing for G6PD deficiency: blood disorder interference, contrived specimens, and fingerstick equivalence and precision. PLoS ONE. 2021;16: e0257560. · DOI
- Zobrist S, Brito M, Garbin E, Monteiro WM, Clementino Freitas S, Macedo M, et al. Evaluation of a point-of-care diagnostic to identify glucose-6-phosphate dehydrogenase deficiency in Brazil. PLoS Negl Trop Dis. 2021;15: e0009649. · DOI
- Alam MS, Kibria MG, Jahan N, Thriemer K, Hossain MS, Douglas NM, et al. Field evaluation of quantitative point of care diagnostics to measure glucose-6-phosphate dehydrogenase activity. PLoS ONE. 2018;13: e0206331. · DOI · Paper page
- Pal S, Bansil P, Bancone G, Hrutkay S, Kahn M, Gornsawun G, et al. Evaluation of a novel quantitative test for glucose-6-phosphate dehydrogenase deficiency: bringing quantitative testing for glucose-6-phosphate dehydrogenase deficiency closer to the patient. Am J Trop Med Hyg. 2018;100:213–21. · DOI · Paper page
- Nekkab N, Lana R, Lacerda M, Obadia T, Siqueira A, Monteiro W, et al. Estimated impact of tafenoquine for Plasmodium vivax control and elimination in Brazil: a modelling study. PLoS Med. 2021;18: e1003535. · DOI
- Ley B, Satyagraha AW, Kibria MG, Armstrong J, Bancone G, Bei AK, et al. Repeatability and reproducibility of a handheld quantitative G6PD diagnostic. PLoS Negl Trop Dis. 2022;16: e0010174. · doi:10.1371/journal.pntd.0010174
- Drain PK, Hyle EP, Noubary F, Freedberg KA, Wilson D, Bishai WR, et al. Evaluating diagnostic point-of-care tests in resource-limited settings. Lancet Infect Dis. 2014;14:239–49. · DOI · Paper page
- Jameel F, Alexeenko A, Bhambhani A, Sacha G, Zhu T, Tchessalov S, et al. Recommended best practices for lyophilization validation 2021 Part II: process qualification and continued process verification. AAPS PharmSciTech. 2021;22:266. · DOI
- Aung TH, Suansomjit C, Tun ZM, Hlaing TM, Kaewkungwal J, Cui L, et al. Prevalence of G6PD deficiency and diagnostic accuracy of a G6PD point-of-care test among a population at risk of malaria in Myanmar. Malar J. 2023;22:143. · DOI
- Garcia LS. Malaria. Clin Lab Med. 2010;30:93–129. · DOI · Paper page
- Llanos-Cuentas A, Manrrique P, Rosas-Aguirre A, Herrera S, Hsiang MS. Tafenoquine for the treatment of Plasmodium vivax malaria. Expert Opin Pharmacother. 2022;23:759–68. · DOI
- Peixoto HM, Brito MAM, Romero GAS, Monteiro WM, de Lacerda MVG, de Oliveira MRF. Rapid diagnostic test for G6PD deficiency in Plasmodium vivax-infected men: a budget impact analysis based in Brazilian Amazon. Trop Med Int Health. 2017;22:21–31. · doi:10.1111/tmi.12800
- McInnes MDF, Moher D, Thombs BD, McGrath TA, Bossuyt PM, the PRISMA-DTA Group, et al. Preferred reporting items for a systematic review and meta-analysis of diagnostic test accuracy studies: the PRISMA-DTA statement. JAMA. 2018;319:388–96. · DOI · Paper page
- Ley B, Thriemer K, Jaswal J, Poirot E, Alam MS, Phru CS, et al. Barriers to routine G6PD testing prior to treatment with primaquine. Malar J. 2017;16:329. · DOI
- Brito-Sousa JD, Murta F, Vitor-Silva S, Sampaio V, Mendes M, Souza B, et al. Quantitative G6PD deficiency screening in routine malaria diagnostic units in the Brazilian Amazon (SAFEPRIM): an operational mixed-methods study. Pathogens. 2022;11:1328. · DOI
- Barker TH, McBride GM, Dias M, Price C, Munn Z. Contextual factors and G6PD diagnostic testing: a scoping review and evidence and gap map. Malar J. 2024;23:241. · DOI
Cited by
Dessie, G., Getnet, M., Getahun, A. B., Mengstie, T. A., Asefa, T., Enyew, E. F., Yewodiaw, T. K., Endale, H. T., & Endalew, H. L. (2026) · Malaria Journal · doi:10.1186/s12936-026-05800-8
Metadata
- Authors
- Martínez, J. C., Vélez-Marín, V., Lopez-Perez, M., Patiño-Lugo, D. F., & Florez, I. D.
- Venue
- Malaria Journal
- Published
- 2024-11-02
- Volume
- 23
- Issue
- 1
- ISSN
- 1475-2875
- Cited by
- 13
- References
- 4
- Language
- en
- Licence
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Funders
- Bill & Melinda Gates Foundation
- Independent Research Fund Denmark (013400123B)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Diagnostic accuracy of the point-of-care standard G6PD test™ (SD Biosensor) for glucose-6-phosphate dehydrogenase deficiency: a systematic review and meta-analysis. https://app.cochat.ai/papers/10.1186/s12936-024-05144-1
- The paper
- Martínez, J. C., Vélez-Marín, V., Lopez-Perez, M., Patiño-Lugo, D. F., & Florez, I. D. (2024). Diagnostic accuracy of the point-of-care standard G6PD test™ (SD Biosensor) for glucose-6-phosphate dehydrogenase deficiency: a systematic review and meta-analysis. Malaria Journal. https://doi.org/10.1186/s12936-024-05144-1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.